Targeted look at residual inflammation after a heart attack
Target Investigation of Residual Inflammation After Non-ST/ ST Elevation Acute Coronary Syndrome - TIRANA (ACS) Prospective REGISTRY
This project will test whether the neutrophil-to-lymphocyte ratio (NLR) from the first routine blood draw can help predict risk of death in adults (18–85) after an acute coronary syndrome treated with PCI.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1600 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | University Hospital Centre Mother Teresa Academic / other |
| Locations | 1 site (Tirana) |
| Trial ID | NCT07026708 on ClinicalTrials.gov |
What this trial studies
This prospective observational registry will enroll adults aged 18–85 admitted with confirmed ACS (STEMI or NSTEMI) treated with percutaneous coronary intervention at the University Hospital Centre Mother Teresa in Tirana. NLR will be calculated from the first complete blood count obtained on admission. Patients will be followed for mortality outcomes to see if admission NLR independently predicts death after ACS. The study uses routine laboratory data to explore a low-cost marker for early risk stratification.
Who should consider this trial
Good fit: Adults aged 18–85 admitted with confirmed ACS (STEMI or NSTEMI) who undergo PCI and can be contacted after discharge are the intended participants.
Not a fit: Patients who die before PCI, those with diagnoses other than ACS or unstable angina, those outside the 18–85 age range, or those without contact information would not be included and are unlikely to benefit.
Why it matters
Potential benefit: If successful, NLR could become a low-cost, widely available marker to identify patients at higher risk after ACS and guide closer follow-up or targeted treatment.
How similar studies have performed: Previous observational studies have linked higher NLR to worse cardiovascular outcomes, but its independent predictive value for post-ACS mortality in this population has not been firmly established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- All patients (undergoing PCI, aged 18-85 years) presenting to the cardiology department or/and the cardiology intensive care unit with a diagnosis of ACS Exclusion Criteria: * Patients presenting to the cardiology department or/and the cardiology intensive care unit with diagnoses other than ACS and/or UA. Patients who died before undergoing PCI and those who did not provide a contact number.
Where this trial is running
Tirana
- Faculty of Medicine Tirana — Tirana, Albania (Recruiting)
Study contacts
- Principal investigator: Andi Rroku, MD — Deutsches Herzzentrum der Charité (DHZC) - Campus Benjamin Franklin
- Study coordinator: Martiola Kola, MD
- Email: martiola.kola@gmail.com
- Phone: 003553410998
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.